NorthRock Partners’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $319K | Sell |
4,572
-401
| -8% | -$28K | 0.01% | 515 |
|
|
2025
Q1 | $366K | Buy |
4,973
+1,291
| +35% | +$94.9K | 0.01% | 428 |
|
|
2024
Q4 | $241K | Buy |
3,682
+300
| +9% | +$19.7K | 0.01% | 529 |
|
|
2024
Q3 | $263K | Buy |
3,382
+50
| +2% | +$3.89K | 0.01% | 536 |
|
|
2024
Q2 | $260K | Sell |
3,332
-12
| -0.4% | -$936 | 0.01% | 510 |
|
|
2024
Q1 | $227K | Sell |
3,344
-721
| -18% | -$48.8K | 0.01% | 550 |
|
|
2023
Q4 | $274K | Buy |
+4,065
| New | +$274K | 0.01% | 473 |
|
|
2023
Q3 | – | Sell |
-3,155
| Closed | -$226K | – | 349 |
|
|
2023
Q2 | $226K | Sell |
3,155
-139
| -4% | -$9.95K | 0.02% | 269 |
|
|
2023
Q1 | $229K | Buy |
+3,294
| New | +$229K | 0.02% | 282 |
|
|
2022
Q3 | – | Sell |
-7,768
| Closed | -$513K | – | 301 |
|
|
2022
Q2 | $513K | Buy |
7,768
+132
| +2% | +$8.72K | 0.05% | 150 |
|
|
2022
Q1 | $507K | Buy |
7,636
+585
| +8% | +$38.8K | 0.05% | 172 |
|
|
2021
Q4 | $411K | Sell |
7,051
-350
| -5% | -$20.4K | 0.03% | 200 |
|
|
2021
Q3 | $444K | Buy |
7,401
+941
| +15% | +$56.5K | 0.04% | 165 |
|
|
2021
Q2 | $387K | Hold |
6,460
| – | – | 0.03% | 167 |
|
|
2021
Q1 | $321K | Sell |
6,460
-4,145
| -39% | -$206K | 0.03% | 166 |
|
|
2020
Q4 | $530K | Sell |
10,605
-9,129
| -46% | -$456K | 0.05% | 123 |
|
|
2020
Q3 | $1.08M | Buy |
19,734
+13,665
| +225% | +$749K | 0.12% | 71 |
|
|
2020
Q2 | $321K | Sell |
6,069
-353
| -5% | -$18.7K | 0.04% | 151 |
|
|
2020
Q1 | $287K | Sell |
6,422
-2,022
| -24% | -$90.4K | 0.04% | 146 |
|
|
2019
Q4 | $421K | Buy |
8,444
+1,053
| +14% | +$52.5K | 0.04% | 169 |
|
|
2019
Q3 | $329K | Buy |
+7,391
| New | +$329K | 0.04% | 155 |
|